MINERALYS THERAPEUTICS INC (MLYS) Fundamental Analysis & Valuation

NASDAQ:MLYS • US6031701013

Current stock price

26.62 USD
-0.55 (-2.02%)
At close:
26.63 USD
+0.01 (+0.04%)
After Hours:

This MLYS fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. MLYS Profitability Analysis

1.1 Basic Checks

  • MLYS had negative earnings in the past year.
  • MLYS had a negative operating cash flow in the past year.
  • MLYS had negative earnings in each of the past 5 years.
  • In the past 5 years MLYS always reported negative operating cash flow.
MLYS Yearly Net Income VS EBIT VS OCF VS FCFMLYS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • MLYS's Return On Assets of -23.37% is fine compared to the rest of the industry. MLYS outperforms 72.53% of its industry peers.
  • Looking at the Return On Equity, with a value of -23.91%, MLYS is in the better half of the industry, outperforming 79.30% of the companies in the same industry.
Industry RankSector Rank
ROA -23.37%
ROE -23.91%
ROIC N/A
ROA(3y)-46.1%
ROA(5y)-67.76%
ROE(3y)-48.9%
ROE(5y)-98.88%
ROIC(3y)N/A
ROIC(5y)N/A
MLYS Yearly ROA, ROE, ROICMLYS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 2025 0 -100 -200 -300

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for MLYS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MLYS Yearly Profit, Operating, Gross MarginsMLYS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. MLYS Health Analysis

2.1 Basic Checks

  • MLYS has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MLYS has been increased compared to 5 years ago.
  • There is no outstanding debt for MLYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
MLYS Yearly Shares OutstandingMLYS Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
MLYS Yearly Total Debt VS Total AssetsMLYS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 88.24 indicates that MLYS is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 88.24, MLYS belongs to the best of the industry, outperforming 98.07% of the companies in the same industry.
  • There is no outstanding debt for MLYS. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 88.24
ROIC/WACCN/A
WACCN/A
MLYS Yearly LT Debt VS Equity VS FCFMLYS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 2025 0 200M 400M 600M

2.3 Liquidity

  • A Current Ratio of 43.76 indicates that MLYS has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 43.76, MLYS belongs to the top of the industry, outperforming 98.84% of the companies in the same industry.
  • MLYS has a Quick Ratio of 43.76. This indicates that MLYS is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 43.76, MLYS belongs to the top of the industry, outperforming 98.84% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 43.76
Quick Ratio 43.76
MLYS Yearly Current Assets VS Current LiabilitesMLYS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 2025 200M 400M 600M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. MLYS Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 34.89% over the past year.
EPS 1Y (TTM)34.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.18%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, MLYS will show a very strong growth in Earnings Per Share. The EPS will grow by 34.31% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y4.09%
EPS Next 2Y-6.76%
EPS Next 3Y20.42%
EPS Next 5Y34.31%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
MLYS Yearly Revenue VS EstimatesMLYS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B
MLYS Yearly EPS VS EstimatesMLYS Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 5 10

More info and screens

Find the best growth stocksShow best growing peers

1

4. MLYS Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MLYS. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for MLYS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MLYS Price Earnings VS Forward Price EarningsMLYS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MLYS Per share dataMLYS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 6

4.3 Compensation for Growth

  • MLYS's earnings are expected to grow with 20.42% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-6.76%
EPS Next 3Y20.42%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MLYS Dividend Analysis

5.1 Amount

  • MLYS does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MLYS Fundamentals: All Metrics, Ratios and Statistics

MINERALYS THERAPEUTICS INC

NASDAQ:MLYS (4/10/2026, 8:00:01 PM)

After market: 26.63 +0.01 (+0.04%)

26.62

-0.55 (-2.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-12
Earnings (Next)05-11
Inst Owners114.84%
Inst Owner Change0%
Ins Owners1.74%
Ins Owner Change-2.72%
Market Cap2.19B
Revenue(TTM)N/A
Net Income(TTM)-154.65M
Analysts84
Price Target50.36 (89.18%)
Short Float %11.41%
Short Ratio7.45
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)22.09%
Min EPS beat(2)17.77%
Max EPS beat(2)26.41%
EPS beat(4)4
Avg EPS beat(4)18.86%
Min EPS beat(4)10.13%
Max EPS beat(4)26.41%
EPS beat(8)5
Avg EPS beat(8)4.31%
EPS beat(12)9
Avg EPS beat(12)15.84%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.89%
PT rev (3m)-0.5%
EPS NQ rev (1m)10.99%
EPS NQ rev (3m)10.99%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 3.39
P/tB 3.39
EV/EBITDA N/A
EPS(TTM)-2.37
EYN/A
EPS(NY)-2.27
Fwd EYN/A
FCF(TTM)-1.73
FCFYN/A
OCF(TTM)-1.73
OCFYN/A
SpS0
BVpS7.85
TBVpS7.85
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -23.37%
ROE -23.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-46.1%
ROA(5y)-67.76%
ROE(3y)-48.9%
ROE(5y)-98.88%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.42%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 43.76
Quick Ratio 43.76
Altman-Z 88.24
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.89%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%59.18%
EPS Next Y4.09%
EPS Next 2Y-6.76%
EPS Next 3Y20.42%
EPS Next 5Y34.31%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y11.08%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-10.68%
EBIT Next 3Y25.4%
EBIT Next 5Y42.33%
FCF growth 1Y14.41%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.37%
OCF growth 3YN/A
OCF growth 5YN/A

MINERALYS THERAPEUTICS INC / MLYS Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for MINERALYS THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to MLYS.


What is the valuation status for MLYS stock?

ChartMill assigns a valuation rating of 1 / 10 to MINERALYS THERAPEUTICS INC (MLYS). This can be considered as Overvalued.


What is the profitability of MLYS stock?

MINERALYS THERAPEUTICS INC (MLYS) has a profitability rating of 1 / 10.


What is the expected EPS growth for MINERALYS THERAPEUTICS INC (MLYS) stock?

The Earnings per Share (EPS) of MINERALYS THERAPEUTICS INC (MLYS) is expected to grow by 4.09% in the next year.